Quanterix Corporation (QTRX)
QTRX Stock Price Chart
Explore Quanterix Corporation interactive price chart. Choose custom timeframes to analyze QTRX price movements and trends.
QTRX Company Profile
Discover essential business fundamentals and corporate details for Quanterix Corporation (QTRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
7 Dec 2017
Employees
471.00
Website
https://www.quanterix.comCEO
Everett V. Cunningham
Description
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
QTRX Financial Timeline
Browse a chronological timeline of Quanterix Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.41, while revenue estimate is $37.46m.
Earnings released on 6 May 2026
EPS came in at -$0.39 falling short of the estimated -$0.31 by -25.81%, while revenue for the quarter reached $36.42m , missing expectations by -1.16%.
Earnings released on 2 Mar 2026
EPS came in at -$0.38 falling short of the estimated -$0.27 by -40.74%, while revenue for the quarter reached $43.86m , beating expectations by +14.76%.
Earnings released on 10 Nov 2025
EPS came in at -$0.36 falling short of the estimated -$0.23 by -56.52%, while revenue for the quarter reached $40.15m , beating expectations by +5.79%.
Earnings released on 7 Aug 2025
EPS came in at -$0.47 falling short of the estimated -$0.41 by -14.63%, while revenue for the quarter reached $24.45m , missing expectations by -36.50%.
Earnings released on 12 May 2025
EPS came in at -$0.53 surpassing the estimated -$0.69 by +23.19%, while revenue for the quarter reached $30.27m , beating expectations by +7.08%.
Earnings released on 17 Mar 2025
EPS came in at -$0.30 falling short of the estimated -$0.27 by -11.11%, while revenue for the quarter reached $34.11m , missing expectations by -2.36%.
Earnings released on 12 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.24 by +8.33%, while revenue for the quarter reached $35.70m , beating expectations by +4.58%.
Earnings released on 8 Aug 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $34.13m , beating expectations by +1.27%.
Earnings released on 7 May 2024
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%, while revenue for the quarter reached $31.79m , beating expectations by +0.54%.
Earnings released on 29 Feb 2024
EPS came in at -$0.33 falling short of the estimated -$0.32 by -3.13%, while revenue for the quarter reached $31.20m , beating expectations by +4.55%.
Earnings released on 6 Nov 2023
EPS came in at -$0.21 surpassing the estimated -$0.37 by +43.24%, while revenue for the quarter reached $31.06m , beating expectations by +9.60%.
Earnings released on 7 Aug 2023
EPS came in at -$0.16 surpassing the estimated -$0.38 by +57.89%, while revenue for the quarter reached $30.87m , beating expectations by +16.33%.
Earnings released on 9 May 2023
EPS came in at -$0.16 surpassing the estimated -$0.38 by +57.89%, while revenue for the quarter reached $28.23m , beating expectations by +11.16%.
Earnings released on 6 Mar 2023
EPS came in at -$0.50 falling short of the estimated -$0.47 by -6.38%, while revenue for the quarter reached $25.61m , missing expectations by -0.67%.
Earnings released on 8 Nov 2022
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $26.36m , beating expectations by +9.74%.
Earnings released on 8 Aug 2022
EPS came in at -$0.67 falling short of the estimated -$0.48 by -39.58%, while revenue for the quarter reached $23.43m , missing expectations by -22.05%.
Earnings released on 10 May 2022
EPS came in at -$0.49 surpassing the estimated -$0.61 by +19.67%, while revenue for the quarter reached $29.55m , beating expectations by +1.54%.
Earnings released on 1 Mar 2022
EPS came in at -$0.55 surpassing the estimated -$0.66 by +16.67%, while revenue for the quarter reached $30.29m , beating expectations by +6.98%.
Earnings released on 4 Nov 2021
EPS came in at -$0.43 falling short of the estimated -$0.36 by -19.44%, while revenue for the quarter reached $26.68m , beating expectations by +11.12%.
Earnings released on 5 Aug 2021
EPS came in at -$0.33 matching the estimated -$0.33, while revenue for the quarter reached $25.37m , meeting expectations.
QTRX Stock Performance
Access detailed QTRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
